contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


ceo-anders-weilandt-presents-chordate-medical-at-investment-event-on-june-9th

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Chordate Medical Holding is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulatory and drug-free treatment technique for chronic migraine and chronic rhinitis. The treatment has proven efficacy according to a clinical study and is marketed in selected markets in the EU and the Middle East. The company is headquartered in Kista.

Chordate Medical Holding

CEO ANDERS WEILANDT PRESENTS CHORDATE MEDICAL AT INVESTMENT EVENT ON JUNE 9THOn Thursday, June 9th, 14:10 CET, Chordates CEO Anders Weilandt will participate on an investment event hosted by...

CEO ANDERS WEILANDT PRESENTS CHORDATE MEDICAL AT INVESTMENT EVENT ON JUNE 9THOn Thursday, June 9th, 14:10 CET, Chordates CEO Anders Weilandt will participate on an investment event hosted by Västra Hamnen Corporate Finance. He will present the latest developments in the company, such as the recently completed first phase of the marketing authorization process in the <a href="https://www.chordate.com/en/news/chordate-medical-completes-first-phase-in-the-us-moves-forward-with-de-novo-application/">United States</a>, the upcoming representative office in <a href="https://www.chordate.com/en/news/chordate-medical-to-establish-representative-office-in-saudi-arabia/">Saudi Arabia</a> and the marketing efforts in the <a href="https://www.chordate.com/en/news/chordate-medical-begins-market-introduction-of-migraine-treatment-in-the-uk/">United Kingdom</a>.The event is a hybrid event that is held for an audience in Studio Malmö and livestreamed on Västra Hamnens <a href="https://www.youtube.com/channel/UCVozGBv7HOVvjXmT8RyAQmw">Youtube channel</a>.Time: June 9th, 14:10 - 14:35 <a href="https://vhcorp.us18.list-manage.com/subscribe?u=f801e2e471257aa2bed117ad7&amp;id=4919f35b91">Registration for physical participation</a> <a href="https://vhcorp.us18.list-manage.com/subscribe?u=f801e2e471257aa2bed117ad7&amp;id=f575d4f4b6">Registration for online participation</a>A recording of the broadcast will be available afterwards on Chordates website and on the Västra Hamnen Corporate Finance <a href="https://www.youtube.com/channel/UCVozGBv7HOVvjXmT8RyAQmw">YouTube channel</a>.About Västra Hamnen Corporate Finance Västra Hamnen Corporate Finance is an independent advisor who assists companies and owners with, for example, raising capital and advising in connection with corporate transactions. The company currently employs 8 people and operates from Malmö. Västra Hamnen Corporate Finance is under the supervision of the Swedish Financial Supervisory Authority.For more information, please contact: Anders Weilandt, CEO Cell: +46 733-874277 e-mail: <a href="mailto:anders.weilandt@chordate.com">anders.weilandt@chordate.com</a>About&nbsp;Chordate Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medicals share is listed on Nasdaq First North Growth Market Stockholm (ticker:&nbsp;CMH). Read more at&nbsp;<a href="https://www.chordate.com/en/">www.chordate.com/en/</a>Chordates Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200&nbsp;250, <a href="mailto:ca@vhcorp.se">ca@vhcorp.se</a>.N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.